Narayana Hrudayalaya Ltd. has informed the Exchange regarding ''Recommendation by the Board to the shareholders, the issuance of Non-Convertible Securities upto Rs. 2,500 Crores.
NH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Smallcap 250 and 5.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Narayana Hrudayalaya's Board, on August 1, 2025, approved the unaudited Q1 FY26 results and recommended seeking shareholder approval to issue debt securities (including Non-Convertible Debentures) up to Rs. 2,500 Crores in a financial year, on a private placement basis, in one or more tranches and currencies. On a consolidated basis, revenue from operations grew about 15% YoY to Rs. 1,507 Crores, while net profit from continuing operations dipped slightly to Rs. 196 Crores from Rs. 201 Crores a year ago. Standalone revenue rose around 8% YoY to Rs. 943 Crores with net profit nearly flat at Rs. 87.4 Crores. The company also disclosed that its NVD subsidiary operations have been classified as discontinued and the merger scheme with MMRHL is awaiting NCLT approval.
The proposed Rs. 2,500 Crores NCD raising limit, if approved by shareholders, gives the company significant headroom to fund expansion, capex, or refinance existing debt, which could modestly pressure earnings through higher finance costs in future quarters. Q1 results were mixed—strong topline growth but flat-to-slightly-lower profits versus last year, so near-term stock reaction may be muted.